ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Kappa opioid receptor control of motivated behavior revisited.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Kappa opioid receptors mediate aversion-and it matters.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Kappa opioid receptor availability correlates with depressive symptom burden in chronic migraine: a preliminary investigation.The journal of headache and pain · 2026Article
- Article
- Modulatory effects of orexin and dynorphin on stress-related alcohol seeking and relapse: pivotal role of the posterior paraventricular nucleus of the thalamus.Frontiers in pharmacology · 2026Review
- Mu-opioid and nociceptin receptors show divergent, cell-type-specific actions in the mesocorticolimbic reward system in opioid use disorder.Frontiers in cellular neuroscience · 2026Review
- Protocol for a systematic review and meta-analysis of the relationship between opioid exposure and dopaminergic measures in humans assessed by nuclear medicine imaging.Frontiers in psychiatry · 2026Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
Since its discovery, the kappa opioid receptor (KOR) has held the curiosity of basic and clinical researchers across disciplines. Recent advances in technologies for measuring and manipulating KOR activity have poised the field for breakthrough discoveries. As paradigms shift, it is paramount that lessons from the foundational literature are synthesized and passed forward to inform future studies. At the same time, the promise of leveraging the KOR system to improve treatment of neuropsychiatric disorders has thus far failed to materialize, highlighting the need for critical evaluation of whether current frameworks have proven reliable and generalizable. To this end, we review the physiology and pharmacology of KORs and dynorphins and their role in motivated behavior from their discovery through present day. We focus on distinct epochs within the literature and, in parallel sections, present (A) a timeline of major findings leading to the frameworks on which current research is based, and (B) critically revisit the empirical support for specific aspects of these conclusions. In particular, we highlight discrepancies which subvert the canon that KORs' essential function is to encode negative affective states. By synthesizing the foundational literature and calling into question long-standing theories of KOR function, we hope to highlight the ideas that should remain foundational moving forward and identify areas that may benefit from reconceptualization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.